Anne Li March 18th, 2017
Metformin may improve survival in kidney cancer patients, especially those with localized renal cell carcinoma (RCC), a new meta-analysis suggests. Yonghua Mi and colleagues of Yongchuan Hospital, Chongqing Medical University, in Chongqing, China, pooled data from 8 original studies involving 254,329 patients with kidney cancer in Asia or North America. Patients receiving metformin had a significant 36% lower risk of death overall and 38% lower risk of cancer-specific death, according to results published online in International Urology and Nephrology. Moreover, metformin use by patients with localized RCC was associated with a significant 37% and 52% lower risk of death overall and cancer-specific death, respectively. The data were significantly heterogeneous for metastatic RCC. No associations were found for cancer-specific survival or progression-free survival.
See original article at: http://www.renalandurologynews.com/kidney-cancer/renal-cell-carcinoma-better-mortality-with-metformin/article/643814/